Illumina buys SomaLogic in bid to expand proteomics reach

US genomics specialist Illumina (Nasdaq: ILMN) has completed its acquisition of proteomics company SomaLogic, adding large-scale protein analysis to its multiomics portfolio and strengthening its push beyond sequencing into faster drug discovery and biomedical research.

“Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024,” said chief executive Jacob Thaysen.

Illumina said the acquisition supports its strategy of building new growth businesses alongside its high-throughput sequencing franchise, while remaining an open and accessible next-generation sequencing platform.